Ritonavir (RTV) is on the World Health Organization’s list of essential medicines for antiretroviral therapy, but can cause hepatotoxicity by unknown mechanisms. Multiple clinical studies found that hepatotoxicity occurred in 100% of participants who were pretreated with rifampicin or efavirenz followed by RTV-containing regimens. Both rifampicin and efavirenz are activators of the pregnane X receptor (PXR), a transcription factor with marked interspecies differences in ligand-dependent activation. Using PXR-humanized mouse models, we recapitulated the RTV hepatotoxicity observed in the clinic. PXR was found to modulate RTV hepatotoxicity through CYP3A4-dependent pathways involved in RTV bioactivation, oxidative stress, and endoplasmic reticulum stress. In summary, the current work demonstrated the essential roles of human PXR and CYP3A4 in RTV hepatotoxicity, which can be applied to guide the safe use of RTV-containing regimens in the clinic.
Although safety of drug candidates is carefully monitored in preclinical and clinical studies using a variety of approaches, drug toxicity may still occur in clinical practice. Therefore, novel approaches are needed to complement the current drug safety evaluation system. Metabolomics comprehensively analyzes the metabolites altered by drug exposure, which can therefore be used to profile drug metabolism, endobiotic metabolism, and drug-microbiota interactions. The information from metabolomic analysis can be used to determine the off-targets of a drug candidate and thus provide a mechanistic understanding of drug toxicity. We herein discuss the opportunities of metabolomics in drug safety evaluation.
Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2). Pregnant women are particularly vulnerable to COVID-19 due to physiological and immunological changes in pregnancy. Understanding their knowledge and preventive practices is essential for guiding maternal-health interventions. This study assessed the knowledge, perceptions, and adoption of preventive measures against COVID-19 among pregnant women attending antenatal care at the Federal Medical Centre (FMC), Jabi, Abuja. A descriptive cross-sectional study was conducted from July to September 2021 among pregnant women selected through multistage sampling. Using a structured, interviewer-administered questionnaire we obtained data on knowledge, perceptions and preventive practices from 120 women participated. Data was analyzed using SPSS version 28 and summarized as descriptive statistics. Awareness of COVID-19 was high (95.8%) among pregnant women. Most respondents demonstrated adequate knowledge of transmission and prevention, including hand hygiene (99.2%), avoidance of crowds (92.5%), and isolation measures (90.0%). Misconceptions persisted, particularly regarding breastfeeding. Only 35.0% agreed that COVID-19 positive mothers can safely breastfeed, while 42.5% were unsure. Vaccine willingness was moderate (54.2%), reflecting hesitancy despite overall good knowledge. We found high level of awareness and generally positive preventive attitudes toward COVID-19 among pregnant women, but gaps remain in breastfeeding knowledge and vaccine acceptance. Targeted health education and strengthened ANC counselling are needed to address misconceptions and support consistent adoption of preventive practices.